MNOV: Genzyme Patent Litigation Could Lead to Significant Payout | MediciNova, Inc.

コンテンツへスキップ

About Us

　　Message from CEO

　　Our Mission

　　Company Profile

　　Management Team

Clinical Development

　　Ongoing Clinical Studies

　 MN-166 (Ibudilast)

　　　　About MN-166 (Ibudilast)

　　　　ALS

　　　　Oncology / Glioblastoma

　　　　DCM

　　　　CIPN

　　　　ARDS / Lung Injury

　 MN-001 (Tipelukast)

　　　　About MN-001（Tipelukast)

　　　　NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Investor Relations

　　Press Release

　　Media Archive

　　Annual Report

　　SEC filing

　　Stock Quote -TSE

　　Stock Quote -Nasdaq

　　Historical Price Lookup

　　Investment Calculator

　　Analyst Coverage

　　Corporate Governance

　　Information Request

Presentation

　　Corporate Presentation & Resarch Reports

　MN-166 Presentation

　　　　Progressive Multiple Sclerosis (Progressive MS)

　　　　Amyotrophic Lateral Sclerosis (ALS)

　　　　Oncology / Glioblastoma

　　　　Substance Dependence and Addiction

　　　　MN-166 (ibudilast) News Articles

　　　　MN-166 (ibudilast) Publications

　　MN-001 Presentation

Contact Us

　　Contact Us

About Us
Clinical Development
Investor Relations
Presentation
Contact Us

MNOV: Genzyme Patent Litigation Could Lead to Significant Payout

Resarch Reports

2022.04.062025.10.16

MediciNova, Inc.

関連記事

Resarch Reports

MNOV: Multiple ‘Shots on Goal’ Provide Substantial Potential Upside

Resarch Reports

MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury

Resarch Reports

MNOV: BARDA Contract to Support Development of MN-166 in ARDS

Resarch Reports

MNOV: Phase 3 Trial Initiated for MN-166 in ALS

Resarch Reports

MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia

Resarch Reports

MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled

MNOV: Ibudilast Identified as Promising Development Candidate in Alcohol Use Disorder and Degenerative Cervical Myelopathy

MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia

Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy

メニュー
検索